BioCentury
ARTICLE | Emerging Company Profile

RIG-ged against cancer

Rigontec's RIG-I agonists may have more tumor-specific effect than TLR agonists

May 18, 2015 7:00 AM UTC

Rigontec GmbH is incorporating lessons from over a decade of research on oligonucleotide therapeutics to develop cancer therapies targeting RIG-I, an immune-stimulating receptor related to toll-like receptors that may have more tumor-specific activity than TLRs.

RIG-I, also known as DEAD box polypeptide 58 (DDX58), is a cytosolic helicase that induces an immune response to and apoptosis of cells infected by double-stranded viruses. Rigontec is developing RIG-I agonists to trigger a similar response against cancer...